Biodegradable lipids for the delivery of active agents
The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
1. A lipid particle comprising:
(i) a nucleic acid,
(ii) 35-65 mol % of a protonatable lipid compound,
(iii) 3-12 mol % distearoylphosphatidylcholine (DSPC),
(iv) 15-45 mol % cholesterol, and
(v) 0.5-10 mol % of a PEG-modified lipid,
wherein the mol % is based on 100% total moles of lipids in the lipid particle,
wherein the protonatable lipid compound comprises a head group, hydrophobic tails, and a central moiety to which the head group and the hydrophobic tails are directly bonded, wherein:
the central moiety is a nitrogen atom;
the hydrophobic tails consist of two hydrophobic tails;
each of the two hydrophobic tails has the formula —R 12 -M 1 -R 13 , wherein
R 12 is a C 4 -C 14 alkyl group, M 1 is a —OC(O)— group, and R 13 is a C 10 -C 20 branched alkyl group;
the chain length of formula —R 12 -M 1 -R 13 is at most 21 atoms; and
the total carbon atom content of each hydrophobic tail is 21 to 26 carbon atoms.
2. The lipid particle of claim 1 , wherein R 13 is branched at the alpha position relative to the —OC(O)— group.
3. The lipid particle of claim 2 , wherein the chain length of formula —R 12 -M 1 -R 13 is 17 atoms.
4. The lipid particle of claim 2 , wherein the nucleic acid comprises RNA.
5. A lipid particle comprising:
(i) a nucleic acid,
(ii) 35-65 mol % of a protonatable lipid compound,
(iii) 3-12 mol % distearoylphosphatidylcholine (DSPC),
(iv) 15-45 mol % cholesterol, and
(v) 0.5-10 mol % of a PEG-modified lipid, wherein the PEG-modified lipid is 1-(monomethoxy-polyethylene glycol)-2,3-dimyristoyl glycerol (PEG-DMG),
wherein the mol % is based on 100% total moles of lipids in the lipid particle,
wherein the protonatable lipid compound comprises a head group, hydrophobic tails, and a central moiety to which the head group and the two hydrophobic tails are directly bonded, wherein:
the central moiety is a nitrogen atom;
the hydrophobic tails consist of two hydrophobic tails;
each of the two hydrophobic tails independently consists of a first hydrophobic chain, an ester group, and a second hydrophobic chain, wherein the first and second hydrophobic chains are aliphatic and linked by the ester group, and the first hydrophobic chain is bonded directly to the central moiety, wherein each ester group is —C(O)O—;
wherein each hydrophobic tail has a total carbon atom content from 17 to 26 carbon atoms; and
wherein one hydrophobic tail has the formula:
wherein
R 13 is a C 13 -C 17 branched alkyl; and
the chain length of the one hydrophobic tail is from 18 to 20 atoms.
6. The lipid particle of claim 5 , wherein, R 13 is a C 17 branched alkyl.
7. The lipid particle of claim 6 , wherein the hydrophobic tail having the formula:
has a chain length of 18 atoms.
8. The lipid particle of claim 5 , wherein R 13 is branched at the alpha position relative to the —C(O)O— group.
9. The lipid particle of claim 8 , wherein the nucleic acid comprises RNA.
10. The lipid particle of claim 8 , wherein the head group consists of a saturated aliphatic group and a hydroxyl group.
11. The lipid particle of claim 2 , wherein the head group consist of a saturated aliphatic group and a hydroxyl group.
12. A method for preparing a lipid particle mixture comprising mixing a first solution comprising an organic solvent, a protonatable lipid compound, distearoylphosphatidylcholine (DSPC), cholesterol, and a PEG-modified lipid, with a second solution comprising a nucleic acid and water to form a lipid particle mixture, wherein the lipid particle comprises
(i) the nucleic acid,
(ii) 35-65 mol % of the protonatable lipid compound,
(iii) 3-12 mol % distearoylphosphatidylcholine (DSPC),
(iv) 15-45 mol % cholesterol, and
(v) 0.5-10 mol % of the PEG-modified lipid,
wherein the mol % is based on 100% total moles of lipids in the lipid particle,
wherein the protonatable lipid compound comprises a head group, hydrophobic tails, and a central moiety to which the head group and the hydrophobic tails are directly bonded, wherein:
the central moiety is a nitrogen atom;
the hydrophobic tails consist of two hydrophobic tails,
each of the two hydrophobic tails has the formula —R 12 -M 1 -R 13 wherein R 12 is a C 4 -C 14 alkyl group, M 1 is a —OC(O)—, and R 13 is a C 10 -C 20 branched alkyl group;
the chain length of formula —R 12 -M 1 -R 13 is at most 21 atoms; and
the total carbon atom content of each hydrophobic tail is 21 to 26 carbon atoms.
13. The method of claim 12 , wherein R 13 is branched at the alpha position relative to the —OC(O)— group.
14. The method of claim 13 , wherein the organic solvent comprises ethanol and the second solution comprises an aqueous buffer.
15. The method of claim 14 , wherein the aqueous buffer is a citrate buffer.
16. The method of claim 15 , further comprising dialyzing or diafiltering the lipid particle mixture.
17. The method of claim 13 , wherein the nucleic acid comprises RNA.
18. The method of claim 13 , wherein the chain length of formula —R 12 -M 1 -R 13 is 17 atoms.
19. The method of claim 13 , wherein the head group consists of a saturated aliphatic group and a hydroxyl group.
20. A method for preparing a lipid particle mixture comprising mixing a first solution comprising an organic solvent, a protonatable lipid compound, distearoylphosphatidylcholine (DSPC), cholesterol, and a PEG-modified lipid, with a second solution comprising a nucleic acid and water to form a lipid particle mixture, wherein the lipid particle comprises
(i) a nucleic acid,
(ii) 35-65 mol % of a protonatable lipid compound,
(iii) 3-12 mol % distearoylphosphatidylcholine (DSPC),
(iv) 15-45 mol % cholesterol, and
(v) 0.5-10 mol % of the PEG-modified lipid, wherein the PEG-modified lipid is 1-(monomethoxy-polyethylene glycol)-2,3-dimyristoyl glycerol (PEG-DMG),
wherein the mol % is based on 100% total moles of lipids in the lipid particle,
wherein the protonatable lipid compound comprises a head group, hydrophobic tails, and a central moiety to which the head group and the hydrophobic tails are directly bonded, wherein:
the central moiety is a nitrogen atom;
the hydrophobic tails consist of two hydrophobic tails;
each of the two hydrophobic tails independently consists of a first hydrophobic chain, an ester group, and a second hydrophobic chain, wherein the first and second hydrophobic chains are aliphatic and linked by the ester group, and the first hydrophobic chain is bonded directly to the central moiety, wherein each ester group is —C(O)O—;
wherein each hydrophobic tail has a total carbon atom content from 17 to 26 carbon atoms; and
wherein one hydrophobic tail has the formula:
wherein:
R 13 is a C 13 -C 17 branched alkyl; and
the chain length of the one hydrophobic tail is from 18 to 20 atoms.
21. The method of claim 20 , wherein R 13 is a C 17 branched alkyl.
22. The method of claim 21 , wherein the hydrophobic tail having the formula:
has a chain length of 18 atoms.
23. The method of claim 20 , wherein R 13 is branched at the alpha position relative to the —C(O)O— group.
24. The method of claim 23 , wherein the nucleic acid comprises RNA.
25. The method of claim 23 , wherein the head group consists of a saturated aliphatic group and a hydroxyl group.
26. The method of claim 21 , wherein the organic solvent comprises ethanol and the second solution comprises an aqueous buffer.
27. The method of claim 26 , wherein the aqueous buffer is a citrate buffer.
28. The method of claim 27 , further comprising dialyzing or diafiltering the lipid particle mixture.